(g)   VLYSAFTWLGYVNSAVNPIIYTTF (SEQ ID NO: 7) and

(h)   an effective analogue or fragment of (a) to (g).

10.(Amended) The method of claim 7 wherein the dopamine receptor is a D2 dopamine receptor and the peptide is selected from the group consisting of

(a) YATLLTLLIAVIVFGNVLVC (SEQ ID NO: 61);

(b) VSLAVADLLVATLVMPWVVY (SEQ ID NO: 60);

(c) TLDVMMCTASILNLCAISID (SEQ ID NO: 59);

(d) RVTVMISIVWVLSFTISCPL (SEQ ID NO: 58);

(e) PAFVVYSSIVSFYVPFIVTL (SEQ ID NO: 57);

(f) LAIVLGVFIICWLPFFITHI (SEQ ID NO: 56); and

(g) LYSAFTWLGYVNSAVNPIIY (SEQ ID NO: 55).

12.(Amended) The method of claim 11 wherein the adrenergic receptor is a β1-adrenergic receptor and the peptide is selected from the group consisting of

(a)   GMGLLMALIVLLIVAGNVLVIVAI (SEQ ID NO: 16);

(b)   IMSLASADLVMGLLVVPFGATIVV (SEQ ID NO: 17)

(c)   ELWTSVDVLCVTASIETLCFIALD (SEQ ID NO: 18)

(d)   RGLVCTVWAISALVSFLPILMHWW (SEQ ID NO: 19)

(e)   RAYAIASSVVSFYVPLCIMAFVYL (SEQ ID NO: 20)

(f)   LGIIMGVFTLCWLPFFLANVVKAF (SEQ ID NO: 21)

(g)   RLFVFFNWLGYANSAFNPIIYCRS (SEQ ID NO: 22); and

(h)   an effective analogue or fragment of (a) to (g).

13.(Amended) The method of claim 11 wherein the receptor is a β1-adrenergic receptor and the peptide is FFNWLGYANSAFNP (SEQ ID NO: 30).

14.(Amended) The method of claim 11 wherein the receptor is an α1A-adrenergic receptor and the peptide is selected from the group consisting of

    (a)   GVGVGFLAAFILMAVAGNLLVILSV (SEQ ID NO: 23);

    (b)   FIVNLAVADLLLSATVLPFSATMEVL (SEQ ID NO: 24);

    (c)   DVWAAVDVLCCTASILSLCTISV (SEQ ID NO: 25);

    (d)   AAILALLWVVALVVSVGPLLGWKEP (SEQ ID NO: 26);

    (e)   AGYAVFSSVCSFYLPMAVIVVMYC (SEQ ID NO: 27);

    (f)   LAIVVGVFVLCWFPFFFVLPLGSL (SEQ ID NO: 28);

    (g)   EGVFKVIFWLGYFNSCVNPLIYPCS (SEQ ID NO: 29); and

    (h)   an effective analogue or fragment of (a) to (g).

15.(Amended) The method of claim 11 wherein the receptor is an α1A-adrenergic receptor and the peptide is VFKVIFWLGYFNSCVN (SEQ ID NO: 31).

25.(Amended) The method of claim 24 wherein the dopamine receptor is the D1 dopamine receptor and the peptide is selected from the group consisting of

    (a)   ILTACFLSLLILSTLLGNTLVCAAV (SEQ ID NO: 9);

    (b)   FFVISLAVSDLLVAVLVMPWKAVAEIA (SEQ ID NO: 10);

    (c)   NIWVAFDIMCSTASILNLCVISVD (SEQ ID NO: 11);

    (d)   AAFILISVAWTLSVLISFIPVQLSW (SEQ ID NO: 12);

    (e)   TYAISSSVISFYIPVAIMIVTYTRI (SEQ ID NO: 13);

    (f)   TLSVIMGVFVCCWLPFFILNCILPFC (SEQ ID NO: 14);

    (g)   [FDSNT] FDVFVWFGWANSSLNPIIYAFNAD (SEQ ID NO: 15) and

    (h)   an effective analogue or fragment of (a) to (g).

26.(Amended) The method of claim 24 wherein the dopamine receptor is a D2 dopamine receptor and the peptide is selected from the group consisting of

    (a)   ATLLTLLIAVIVFGNVLVCMAVS (SEQ ID NO: 1);

(b)   LIVSLAVADLLVATLMPWVVYLEVV <u>(SEQ ID NO: 2)</u>;

(c)   IVFTLDVMMCTASILNLCAISI <u>(SEQ ID NO: 3)</u>;

(d)   VTVMISIVWVLSFTISCPLLFGL <u>(SEQ ID NO: 4)</u>;

(e)   PAFVVYSSIVSFYVPFIVTLLVYI <u>(SEQ ID NO: 5)</u>;

(f)   MLAIVLGVFIICWLPFFITHILN <u>(SEQ ID NO: 6)</u>;

(g)   VLYSAFTWLGYVNSAVNPIIYTTF <u>(SEQ ID NO: 7)</u> and

(h)   an effective analogue or fragment of (a) to (g).

27.(Amended) The method of claim 24 wherein the dopamine receptor is a D2 dopamine receptor and the peptide is selected from the group consisting of

(a) YATLLTLLIAVIVFGNVLVC <u>(SEQ ID NO: 61)</u>;

(b) VSLAVADLLVATLVMPWVVY <u>(SEQ ID NO: 60)</u>;

(c) TLDVMMCTASILNLCAISID <u>(SEQ ID NO: 59)</u>;

(d) RVTVMISIVWVLSFTISCPL <u>(SEQ ID NO: 58)</u>;

(e) PAFVVYSSIVSFYVPFIVTL <u>(SEQ ID NO: 57)</u>;

(f) LAIVLGVFIICWLPFFITHI <u>(SEQ ID NO: 56)</u>; and

(g) LYSAFTWLGYVNSAVNPIIY <u>(SEQ ID NO: 55)</u>.

30.(Amended) The method of claim 29 wherein the adrenergic receptor is a β1-adrenergic receptor and the peptide is selected from the group consisting of

(a)   GMGLLMALIVLLIVAGNVLVIVAI <u>(SEQ ID NO: 16)</u>;

(b)   IMSLASADLVMGLLVVPFGATIVV <u>(SEQ ID NO: 17)</u>

(c)   ELWTSVDVLCVTASIETLCFIALD <u>(SEQ ID NO: 18)</u>

(d)   ~~RGLVCTVWAISALVSFLPILMHWW (SEQ ID NO: 19)~~

(e)   RAYAIASSVVSFYVPLCIMAFVYL <u>(SEQ ID NO: 20)</u>

(f)   LGIIMGVFTLCWLPFFLANVVKAF <u>(SEQ ID NO: 21)</u>

(g)   RLFVFFNWLGYANSAFNPIIYCRS <u>(SEQ ID NO: 22)</u>; and

(h)   an effective analogue or fragment of (a) to (g).

31.   The method of claim 29 wherein the receptor is a β1-adrenergic receptor and the peptide is FFNWLGYANSAFNP (SEQ ID NO: 30).

33.(Amended) The method of claim 29 wherein the adrenergic receptor is an α1A-adrenergic receptor and the peptide is selected from the group consisting of

     (a)   GVGVGFLAAFILMAVAGNLLVILSV (SEQ ID NO: 23);

     (b)   FIVNLAVADLLLSATVLPFSATMEVL (SEQ ID NO: 24);

     (c)   DVWAAVDVLCCTASILSLCTISV (SEQ ID NO: 25);

     (d)   AAILALLWVVALVVSVGPLLGWKEP (SEQ ID NO: 26);

     (e)   AGYAVFSSVCSFYLPMAVIVVMYC (SEQ ID NO: 27);

     (f)   LAIVVGVFVLCWFPFFFVLPLGSL (SEQ ID NO: 28);

     (g)   EGVFKVIFWLGYFNSCVNPLIYPCS (SEQ ID NO: 29); and

     (h)   an effective analogue or fragment of (a) to (g).

34.(Amended) The method of claim 29 wherein the receptor is an [αA1] α1A-adrenergic receptor and the peptide is VFKVIFWLGYFNSCVN (SEQ ID NO: 31).

49.(Amended) The antagonist of claim 48 wherein the dopamine receptor is a D1 dopamine receptor and the antagonist is selected from the group consisting of

     (a)   ILTACFLSLLILSTLLGNTLVCAAV (SEQ ID NO: 9);

     (b)   FFVISLAVSDLLVAVLVMPWKAVAEIA (SEQ ID NO: 10);

     (c)   NIWVAFDIMCSTASILNLCVISVD (SEQ ID NO: 11);

     (d)   AAFILISVAWTLSVLISFIPVQLSW (SEQ ID NO: 12);

     (e)   TYAISSSVISFYIPVAIMIVTYTRI (SEQ ID NO: 13);

     (f)   TLSVIMGVFVCCWLPFFILNCILPFC (SEQ ID NO: 14);

     (g)   [FDSNT] FDVFVWFGWANSSLNPIIYAFNAD (SEQ ID NO: 15) and

(h)   an effective analogue or fragment of (a) to (g).

50.(Amended) The antagonist of claim 48 wherein the dopamine receptor is a D2 dopamine receptor and the antagonist is selected from the group consisting of

(a)   ATLLTLLIAVIVFGNVLVCMAVS (SEQ ID NO: 1);

(b)   LIVSLAVADLLVATLMPWVVYLEVV (SEQ ID NO: 2);

(c)   IVFTLDVMMCTASILNLCAISI (SEQ ID NO: 3);

(d)   VTVMISIVWVLSFTISCPLLFGL (SEQ ID NO: 4);

(e)   PAFVVYSSIVSFYVPFIVLLVYI (SEQ ID NO: 5);

(f)   MLAIVLGVFIICWLPFFITHILN (SEQ ID NO: 6);

(g)   VLYSAFTWLGYVNSAVNPIIYTTF (SEQ ID NO: 7) and

(h)   an effective analogue or fragment of (a) to (g).

51.(Amended) The antagonist of claim 48 wherein the dopamine receptor is a D2 dopamine receptor and the antagonist is selected from the group consisting of

(a) YATLLTLLIAVIVFGNVLVC (SEQ ID NO: 61);

(b) VSLAVADLLVATLVMPWVVY (SEQ ID NO: 60);

(c) TLDVMMCTASILNLCAISID (SEQ ID NO: 59);

(d) RVTVMISIVWVLSFTISCPL (SEQ ID NO: 58);

(e) PAFVVYSSIVSFYVPFIVTL (SEQ ID NO: 57);

(f) LAIVLGVFIICWLPFFITHI (SEQ ID NO: 56); and

(g) LYSAFTWLGYVNSAVNPIIY (SEQ ID NO: 55).

53.(Amended) The antagonist of claim 52 wherein the adrenergic receptor is a β1-adrenergic receptor and the antagonist is selected from the group consisting of

(a)   GMGLLMALIVLLIVAGNVLVIVAI (SEQ ID NO: 16);

(b)   IMSLASADLVMGLLVVPFGATIVV (SEQ ID NO: 17)

(c)   ELWTSVDVLCVTASIETLCVIALD (SEQ ID NO: 18)

(d)   RGLVCTVWAISALVSFLPILMHWW <u>(SEQ ID NO: 19)</u>

(e)   RAYAIASSVVSFYVPLCIMAFVYL <u>(SEQ ID NO: 20)</u>

(f)   LGIIMGVFTLCWLPFFLANVVKAF <u>(SEQ ID NO: 21)</u>

(g)   RLFVFFNWLGYANSAFNPIIYCRS <u>(SEQ ID NO: 22)</u>; and

(h)   an effective analogue or fragment of (a) to (g).

54.(Amended) The antagonist of claim 52 wherein the receptor is a β1-adrenergic receptor and the antagonist is FFNWLGYANSAFNP <u>(SEQ ID NO: 30)</u>.

55.(Amended) The antagonist of claim 52 wherein the receptor is an α1A-adrenergic receptor and the antagonist is selected from the group consisting of

(a)   GVGVGFLAAFILMAVAGNLLVILSV <u>(SEQ ID NO: 23)</u>;

(b)   FIVNLAVADLLLSATVLPFSATMEVL <u>(SEQ ID NO: 24)</u>;

(c)   DVWAAVDVLCCTASILSLCTISV <u>(SEQ ID NO: 25)</u>;

(d)   AAILALLWVVALVVSVGPLLGWKEP <u>(SEQ ID NO: 26)</u>;

(e)   AGYAVFSSVCSFYLPMAVIVVMYC <u>(SEQ ID NO: 27)</u>;

(f)   LAIVVGVFVLCWFPFFFVLPLGSL <u>(SEQ ID NO: 28)</u>;

(g)   EGVFKVIFWLGYFNSCVNPLIYPCS <u>(SEQ ID NO: 29)</u>; and

(h)   an effective analogue or fragment of (a) to (g).

56.(Amended) The antagonist of claim 52 wherein the receptor is an α1A-adrenergic receptor and the antagonist is VFKVIFWLGYFNSCVN <u>(SEQ ID NO: 31)</u>.

REMARKS

In the "Notice to File Missing Parts - Filing Date Granted" mailed July 31, 1996 it was noted that the present application was complete except for compliance with the Sequence Listing Rules. The present amendment brings the application into compliance with the rules by providing a paper copy and computer readable form of the Sequence Listing and by inserting at appropriate